ACRS stock forecast
Our latest prediction for Aclaris Therapeutics, Inc.'s stock price was made on the June 27, 2019 when the stock price was at 2.13$.
In the short term (2weeks), ACRS's stock price should underperform the market by -1.07%. During that period the price should oscillate between -11.99% and +21.13%.
In the medium term (3months), ACRS's stock price should outperform the market by 4.44%. During that period the price should oscillate between -23.62% and +49.86%.Get email alerts
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
At the moment the company generates 14M USD in revenues.
On its last earning announcement, the company reported a loss of -3.96$ per share.
The book value per share is 5.62$
Three months stock forecastJune 27, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|